Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022
Introduction
Lennox-Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy, which, in the majority of cases, manifests in children most commonly before the age of 8 years [1], [2], [3], but can also, more rarely, first present in adulthood [2], [4]. The syndrome was first described in 1966 [1] and is characterized by three key features: multiple seizure types (including tonic, atonic, tonic-atonic, and atypical absence seizures); the presence of diffuse slow spike–wave activity during wakefulness detected by electroencephalogram (EEG); and intellectual disability [1], [5]. However, these characteristics are not always present at onset and may develop over time. Furthermore, due to the highly heterogeneous underlying etiology of LGS (genetic, structural, combinations of structural and genetic [e.g., tuberous sclerosis], or unknown), this syndrome cannot be considered as one disease, but rather an electro-clinical entity. Taken together, this often makes early and accurate diagnosis of LGS challenging [4], [5], [6].
To date, four therapeutic anti-seizure medication (ASM) options have received US Food and Drug Administration and European Medicines Agency approval for the treatment of seizures associated with LGS; these are cannabidiol, lamotrigine, rufinamide, and topiramate [7], [8], [9], [10], [11], [12], [13], [14]. In the US, clobazam and felbamate are also indicated for LGS [15], [16]. Furthermore, carisbamate, fenfluramine, perampanel, and soticlestat are under development/being evaluated for the treatment of LGS (source: clinicaltrials.gov search, June 2021). This manuscript focuses on rufinamide, which is indicated for use as adjunctive treatment of seizures associated with LGS in patients aged ≥1 year [12].
The safety and efficacy of rufinamide has been demonstrated in two phase III studies and their open-label extensions in patients aged 4 to 30 years [17], [18], [19], [20]. In addition, a long-term phase III study of rufinamide treatment in patients with LGS aged 1 to <4 years showed that adjunctive rufinamide is well tolerated in pediatric patients, with similar behavioral outcomes to other ASMs [21]. The aim of this post hoc analysis of data from Study 022 was to assess the safety and efficacy of adjunctive rufinamide for the treatment of children (aged <16 years) and adults (aged ≥16 years) with LGS, which has not been previously reported in detail.
Section snippets
Methods
Full methods of Study 022 have been published previously [17]. Briefly, Study 022 was a randomized, double-blind, placebo-controlled, multicenter phase III study comprising a 28-day baseline period followed by an 84-day treatment period (14-day titration period and 70-day maintenance period). Patients aged 4 to 30 years with LGS and a history of multiple seizure types (including tonic-atonic or astatic seizures and atypical absence seizures with ≥90 seizures/month in the month prior to
Patients
Of a total of 138 patients, 74 patients received rufinamide (<16 years: n = 49; ≥16 years: n = 25) and 64 received placebo (<16 years: n = 43; ≥16 years: n = 21) during the core study and were included in this analysis. Patient demographics at baseline were generally similar between treatment groups (Table 1).
Patients aged <16 years were exposed to rufinamide for a mean (standard deviation [SD]) of 79.2 (21.2) days, compared with 81.5 (17.2) days for patients receiving placebo. For patients
Discussion
Adjunctive rufinamide has demonstrated favorable safety and efficacy for the treatment of total and tonic-atonic seizures in patients with LGS in Study 022 [17]. In this post hoc analysis from Study 022, rufinamide was generally well tolerated and efficacious in patients with LGS, irrespective of patient age. A slightly higher number of children discontinued rufinamide due to a TEAE or reported a serious TEAE compared with adults, which may be due to younger patients being more closely
Conclusions
Overall, these data confirm that rufinamide is efficacious and well tolerated in the treatment of seizures in both children (aged <16 years) and adults (≥16 years) with LGS. The limitation of seizures being recorded in seizure diaries alone without supporting EEG data should be noted.
Funding
Study 022 was sponsored by Eisai Inc. and conducted by Novartis Pharmaceuticals.
Disclosures
Alexis Arzimanoglou, authorized by his institution collaborations, has served as an advisor, consultant, or speaker for Amzell, Arvelle, Biomarin, Eisai, GW Pharmaceuticals, Sanofi, Shire, Takeda, UCB Pharma, and Zogenix. He has received authorship royalties from Elsevier, JLE publications, McKeith Press, and Wiley publications. He has also received research and educational grants, paid to his institution, from Caixa Bank Foundation – Spain Foundation (Spain), Eisai, the European Commission, GW
Acknowledgements
Medical writing support, under the direction of the authors, was provided by Laura George, PhD, on behalf of CMC AFFINITY, McCann Health Medical Communications, funded by Eisai Inc., in accordance with Good Publication Practice (GPP3) guidelines.
References (24)
- et al.
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology
Lancet Neurol
(2009) - et al.
Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients
Epilepsy Behav
(2020) - et al.
Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan
Epilepsy Res
(2014) - et al.
Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial
Epilepsy Res
(2016) - et al.
Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303
Eur J Paediatr Neurol
(2019) - et al.
Rufinamide efficacy and safety in children aged 1–4 years with Lennox-Gastaut syndrome
Brain Dev
(2018) - et al.
Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome
Epilepsia
(1966) - et al.
ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology
Epilepsia
(2017) - et al.
Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations
Front Neurol
(2017) - et al.
All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome... but many do
Epileptic Disord
(2011)
Cited by (3)
The past, present and future of drug therapy for epilepsy
2023, Chinese Journal of Contemporary Neurology and Neurosurgery